CA3240651A1 - Dsrna, preparation method therefor and use thereof - Google Patents

Dsrna, preparation method therefor and use thereof Download PDF

Info

Publication number
CA3240651A1
CA3240651A1 CA3240651A CA3240651A CA3240651A1 CA 3240651 A1 CA3240651 A1 CA 3240651A1 CA 3240651 A CA3240651 A CA 3240651A CA 3240651 A CA3240651 A CA 3240651A CA 3240651 A1 CA3240651 A1 CA 3240651A1
Authority
CA
Canada
Prior art keywords
seq
group
nhac
dsrna
strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240651A
Other languages
English (en)
French (fr)
Inventor
Yunfei Li
Zhen Zhang
Zhe HOU
Jun GENG
Jianyu Zhang
Yaqin ZHOU
Longfei HUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuojie Biotech Shanghai Co Ltd
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of CA3240651A1 publication Critical patent/CA3240651A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3240651A 2021-12-16 2022-12-16 Dsrna, preparation method therefor and use thereof Pending CA3240651A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111542797.4 2021-12-16
CN202111542797 2021-12-16
PCT/CN2022/139488 WO2023109938A1 (zh) 2021-12-16 2022-12-16 一种dsRNA、其制备方法及应用

Publications (1)

Publication Number Publication Date
CA3240651A1 true CA3240651A1 (en) 2023-06-22

Family

ID=86774893

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240651A Pending CA3240651A1 (en) 2021-12-16 2022-12-16 Dsrna, preparation method therefor and use thereof

Country Status (6)

Country Link
JP (1) JP2025500860A (https=)
KR (1) KR20240116537A (https=)
CN (1) CN118302526A (https=)
CA (1) CA3240651A1 (https=)
TW (1) TW202334425A (https=)
WO (1) WO2023109938A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125636A1 (zh) * 2022-12-16 2024-06-20 上海拓界生物医药科技有限公司 Toll样受体调节剂与dsRNA的联合治疗
CN119816597A (zh) * 2023-08-10 2025-04-11 石药集团中奇制药技术（石家庄）有限公司 一种抑制HBV基因表达的dsRNA分子及其应用
CN116854754B (zh) 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
CN118638166B (zh) 2024-08-15 2024-12-17 北京悦康科创医药科技股份有限公司 含有三氮唑结构的GalNAc化合物及其寡核苷酸缀合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101773551B1 (ko) * 2008-10-15 2017-08-31 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
EA024762B9 (ru) * 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
EP3719127A4 (en) * 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN111378655B (zh) * 2018-12-28 2024-03-19 苏州瑞博生物技术股份有限公司 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
AU2020280439B2 (en) * 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
KR20220011689A (ko) * 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도

Also Published As

Publication number Publication date
CN118302526A (zh) 2024-07-05
KR20240116537A (ko) 2024-07-29
WO2023109938A1 (zh) 2023-06-22
TW202334425A (zh) 2023-09-01
JP2025500860A (ja) 2025-01-15

Similar Documents

Publication Publication Date Title
CA3240651A1 (en) Dsrna, preparation method therefor and use thereof
EP4194553A1 (en) Modified sirna with reduced off-target activity
JP7667775B2 (ja) ヌクレオチド類似体を含有するオリゴヌクレオチド
JP7842850B2 (ja) １’－アルキル修飾リボース誘導体及び使用方法
CA3225632A1 (en) Nucleic acid ligand and conjugate thereof, and preparation method therefor and use thereof
JP2022088596A (ja) ＨＣＶ治療に対するβ－Ｄ－２’－デオキシ－２’－α－フルオロ－２’－β－Ｃ－置換－２－修飾－Ｎ６－置換プリンヌクレオチド
JP2021517126A (ja) ヌクレオチド前駆体、ヌクレオチド類似体およびこれを含むオリゴマー化合物
CA3187220A1 (en) Systemic delivery of oligonucleotides
WO2009086192A1 (en) Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
EP4232455A2 (en) Novel ligands for asialoglycoprotein receptor
CA3238317A1 (en) Sirna targeting angiotensinogen and pharmaceutical use of sirna
EP4328310A1 (en) Sirna targeting 17b-hydroxysteroid dehydrogenase type 13 and sirna conjugate
JP2024532271A (ja) 官能化ｎ－アセチルガラクトサミンアナログ
US20250223594A1 (en) Modified double-stranded oligonucleotide molecule, modified double-stranded oligonucleotide conjugate, and use thereof
CN116615542A (zh) 寡核苷酸的全身递送
CN118339294A (zh) 一种dsRNA、其制备方法及应用
EP4467645A1 (en) Dsrna, use thereof and preparation method therefor
EA052687B1 (ru) дцРНК, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ
RU2849194C1 (ru) МОДИФИЦИРОВАННАЯ миРНК С ПОНИЖЕННОЙ НЕЦЕЛЕВОЙ АКТИВНОСТЬЮ
US12098371B2 (en) Lipid-pegylated compounds, preparations and uses thereof
WO2025157273A1 (en) Two or more nucleic acid molecules connected by a linker
WO2025005265A1 (ja) 毒性が低減されたアンチセンスオリゴヌクレオチド
EA052594B1 (ru) Конъюгат нуклеиновой кислоты и лиганда, способ его получения и его применения
WO2025143262A1 (ja) カルバモイルエチル修飾を含有する二本鎖ｒｎａ
WO2026086824A1 (zh) 双链寡核苷酸、缀合物和组合物以及它们的用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251104